Literature DB >> 28972022

Risk factors for extraophthalmic involvement and treatment outcomes in patients with IgG4-related ophthalmic disease.

Jinku Park1, Min Joung Lee2, Namju Kim3, Ji Eun Kim4, Sun-Won Park5, Ho-Kyung Choung6, Sang In Khwarg7.   

Abstract

BACKGROUND/AIM: To analyse the clinical risk factors for extraophthalmic involvement and treatment outcomes in patients with IgG4-related ophthalmic disease (IgG4-ROD) in Korea.
METHODS: We retrospectively reviewed medical records of 42 patients diagnosed with IgG4-ROD confirmed by a surgical biopsy during the 7-year period, between January 2009 and March 2015, at three tertiary referral centres in Korea. Data regarding patients' demographics, clinical characteristics and radiological findings were obtained. The relapse rate was compared between systemic steroids only and combined immunosuppressant therapy.
RESULTS: The mean patient age was 55.2 years (male:female ratio, 1:1). Based on the primary orbital structure affected, the IgG4-RODs were classified as dacryoadenitis (52.4%), orbital soft tissue inflammation (21.4%), trigeminal nerve involvement (11.9%) and myositis (9.5%). Extraophthalmic involvement (n=21) was associated with bilateral involvement (p=0.004), longer symptom duration (p=0.033) and a higher serum IgG4 level (p=0.034). Initial treatment regimens included attentive observation (n=7), prednisolone alone (n=22) and prednisolone plus immunosuppressive agent (n=13). During follow-up (mean, 24 months), 13 patients (37.1%) experienced relapse. In the extraophthalmic involvement group, steroid therapy alone resulted in a significantly higher relapse rate than combined immunosuppressant treatment (p=0.028).
CONCLUSION: Bilateral involvement, longer symptom duration and higher IgG4 levels were significant risk factors for extraophthalmic involvement in Korean patients with IgG4-ROD. In patients with an extraophthalmic involvement, prednisolone combined with an immunosuppressive agent was more effective for preventing recurrence than prednisolone alone. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  inflammation; lacrimal gland; orbit; pathology

Mesh:

Substances:

Year:  2017        PMID: 28972022     DOI: 10.1136/bjophthalmol-2017-310584

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  10 in total

1.  A clinicopathological study on IgG4-related ophthalmic disease.

Authors:  Yuka Suimon; Satoru Kase; Kan Ishijima; Hiromi Kanno-Okada; Susumu Ishida
Journal:  Int J Ophthalmol       Date:  2018-09-18       Impact factor: 1.779

Review 2.  Inflammatory Disorders of the Skull Base: a Review.

Authors:  Pria Anand; Bart K Chwalisz
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

3.  Colon cancer and IgG4-related disease with orbital inflammation and bilateral optic perineuritis: A case report.

Authors:  Stephanie Lemaitre; Gemma Mateu Esquerda; Antoni Castro Guardiola; Jordi Teruel Agustin; Nicolae Sanda; Miguel González-Candial
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

4.  Magnetic resonance imaging indicator of the causes of optic neuropathy in IgG4-related ophthalmic disease.

Authors:  Jing Li; Yan Zhang; Hang Zhou; Lei Wang; Zhenchang Wang; Hongyang Li
Journal:  BMC Med Imaging       Date:  2019-06-18       Impact factor: 1.930

5.  Clinical features and relapse risks of IgG4-related ophthalmic disease: a single-center experience in China.

Authors:  Zhen Zhao; Dapeng Mou; Ziqiao Wang; Qiaozhu Zeng; Zhenfan Wang; Jimeng Xue; Limin Ren; Yanying Liu; Yin Su
Journal:  Arthritis Res Ther       Date:  2021-03-31       Impact factor: 5.156

6.  Radiologic imaging shows variable accuracy in diagnosing orbital inflammatory disease and assessing its activity.

Authors:  Min Joung Lee; Bronwyn E Hamilton; David Pettersson; Kimberly Ogle; Jennifer Murdock; Roger A Dailey; John D Ng; Eric A Steele; Rohan Verma; Stephen R Planck; Tammy M Martin; Dongseok Choi; James T Rosenbaum
Journal:  Sci Rep       Date:  2020-12-14       Impact factor: 4.379

7.  Ophthalmic involvement disparities in clinical characteristics of IgG4-related disease: a retrospective study of 573 patients.

Authors:  Linyang Gan; Xuan Luo; Yunyun Fei; Linyi Peng; Jiaxin Zhou; Jieqiong Li; Hui Lu; Zheng Liu; Panpan Zhang; Xiaowei Liu; Wen Zhang
Journal:  BMC Ophthalmol       Date:  2021-12-27       Impact factor: 2.209

8.  Pathological count of IgG4-positive plasmacytes suggests extraophthalmic involvement and relapse in patients with IgG4-related ophthalmic disease: a retrospective study.

Authors:  Yiqun Yuan; Fengxi Meng; Hui Ren; Han Yue; Kang Xue; Rui Zhang
Journal:  Arthritis Res Ther       Date:  2022-04-01       Impact factor: 5.156

9.  Debulking Surgery Combined with Low-Dose Oral Prednisolone and Azathioprine for Intractable IgG4-Related Orbital Disease: A Case Report.

Authors:  Hua-Hsuan Kuo; Chen-Hung Chen; Shu-Ya Wu
Journal:  Medicina (Kaunas)       Date:  2021-05-04       Impact factor: 2.430

10.  The natural course of IgG4-related ophthalmic disease after debulking surgery: a single-centre retrospective study.

Authors:  Jun Ominato; Tokuhide Oyama; Hiroyuki Cho; Naoya Shiozaki; Hajime Umezu; Jun Takizawa; Takeo Fukuchi
Journal:  BMJ Open Ophthalmol       Date:  2019-08-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.